HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status

Overexpression of HER2 is an important prognostic marker, and the only predictive biomarker of response to HER2-targeted therapies in invasive breast cancer. HER2-HER3 dimer has been shown to drive proliferation and tumor progression, and targeting of this dimer with pertuzumab alongside chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Weitsman, Gregory, Barber, Paul R., Nguyen, Lan K., Lawler, Katherine, Patel, Gargi, Woodman, Natalie, Kelleher, Muireann T., Pinder, Sarah E., Rowley, Mark, Ellis, Paul A., Purushotham, Anand D., Coolen, Anthonius C., Kholodenko, Boris N., Vojnovic, Borivoj, Gillett, Cheryl, Ng, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239455/
https://www.ncbi.nlm.nih.gov/pubmed/27618787
http://dx.doi.org/10.18632/oncotarget.9963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239455/
https://www.ncbi.nlm.nih.gov/pubmed/27618787
http://dx.doi.org/10.18632/oncotarget.9963

Ejemplares similares